Sublingual Delivery of Frovatriptan: An Indication of Potential Alternative Route

Abstract

Frovatriptan, a 5-HT1B and 5-HT1D receptor agonist, is used for the treatment of acute migraine attack. This molecule is classified into second line therapy because of its slow onset of action (peak response obtained after 4 hours of administration) and low bioavailability (25%). Moreover, its therapy is the most costly among all triptans. Attempt has been… (More)
DOI: 10.1155/2014/675868

Topics

10 Figures and Tables

Slides referencing similar topics